Sanara MedTech (NASDAQ:SMTI) Trading 2% Higher – What’s Next?

Sanara MedTech Inc. (NASDAQ:SMTI)’s share price shot up 2% during mid-day trading on Monday . The stock traded as high as $24.35 and last traded at $23.56. 58,532 shares traded hands during mid-day trading, an increase of 56% from the average session volume of 37,598 shares. The stock had previously closed at $23.10.

Analysts Set New Price Targets

Several equities research analysts recently commented on SMTI shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, HC Wainwright cut their price target on Sanara MedTech from $54.00 to $36.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sanara MedTech has a consensus rating of “Hold” and an average price target of $41.00.

Sanara MedTech Price Performance

The firm’s fifty day simple moving average is $23.82 and its 200-day simple moving average is $27.89. The firm has a market capitalization of $209.68 million, a PE ratio of -5.58 and a beta of 1.06. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.33. The firm had revenue of $26.33 million for the quarter, compared to analysts’ expectations of $26.63 million. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. On average, research analysts forecast that Sanara MedTech Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Sanara MedTech by 3.4% during the third quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after purchasing an additional 6,049 shares in the last quarter. Stonebridge Wealth Management LLC purchased a new position in Sanara MedTech in the 2nd quarter worth about $3,397,000. Marshall Wace LLP lifted its stake in Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after acquiring an additional 42,237 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Sanara MedTech by 343.4% during the 3rd quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after acquiring an additional 24,305 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of Sanara MedTech during the 2nd quarter valued at about $382,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.